Population clinical pharmacology of children: modelling covariate effects
- PMID: 16807729
- DOI: 10.1007/s00431-006-0189-x
Population clinical pharmacology of children: modelling covariate effects
Abstract
Introduction: Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically.
Discussions: Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
Conclusion: Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications.
Similar articles
-
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.Br J Clin Pharmacol. 2007 Jan;63(1):75-84. doi: 10.1111/j.1365-2125.2006.02725.x. Epub 2006 Jul 21. Br J Clin Pharmacol. 2007. PMID: 16869817 Free PMC article.
-
Population clinical pharmacology of children: general principles.Eur J Pediatr. 2006 Nov;165(11):741-6. doi: 10.1007/s00431-006-0188-y. Epub 2006 Jun 29. Eur J Pediatr. 2006. PMID: 16807730 Review.
-
Mechanistic basis of using body size and maturation to predict clearance in humans.Drug Metab Pharmacokinet. 2009;24(1):25-36. doi: 10.2133/dmpk.24.25. Drug Metab Pharmacokinet. 2009. PMID: 19252334 Review.
-
All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology.Clin Pharmacokinet. 2025 Feb;64(2):173-192. doi: 10.1007/s40262-024-01444-6. Epub 2024 Dec 7. Clin Pharmacokinet. 2025. PMID: 39644458 Free PMC article. Review.
-
Population pharmacokinetic investigation of actinomycin-D in children and young adults.J Clin Pharmacol. 2008 Jan;48(1):35-42. doi: 10.1177/0091270007310383. J Clin Pharmacol. 2008. PMID: 18094218
Cited by
-
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.Antimicrob Agents Chemother. 2007 Oct;51(10):3720-5. doi: 10.1128/AAC.00318-07. Epub 2007 Jul 23. Antimicrob Agents Chemother. 2007. PMID: 17646418 Free PMC article.
-
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.Br J Clin Pharmacol. 2010 Jul;70(1):88-101. doi: 10.1111/j.1365-2125.2010.03662.x. Br J Clin Pharmacol. 2010. PMID: 20642551 Free PMC article. Clinical Trial.
-
Optimal study design for pioglitazone in septic pediatric patients.J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):433-47. doi: 10.1007/s10928-011-9202-8. Epub 2011 Jun 11. J Pharmacokinet Pharmacodyn. 2011. PMID: 21667139 Free PMC article.
-
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.Br J Clin Pharmacol. 2014 Jun;77(6):1051-63. doi: 10.1111/bcp.12276. Br J Clin Pharmacol. 2014. PMID: 24977292 Free PMC article.
-
Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):29-43. doi: 10.1007/s10928-015-9452-y. Epub 2015 Nov 14. J Pharmacokinet Pharmacodyn. 2016. PMID: 26578442 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources